索拉非尼联合斑螯酸钠维生素B6对经导管动脉化疗栓塞术治疗原发性肝癌患者的近期疗效和安全性研究

Short-term Efficacy and Safety of Sorafenib Combined with Disodium Cantharidinate Vitamin B6 in Patients with Transcatheter Arterial Chemoembolization for Primary Liver Cancer

目的:探究索拉非尼联合斑蝥酸钠维生素B6对经导管动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗的原发性肝癌患者的治疗效果以及对患者血清血管内皮生长因子(vascular endothelial growth factor,VEGF)和肿瘤标志物水平的影响。方法:选取我院2018年12月~2019年12月收治的原发性肝癌患者76例。将患者随机分为观察组和对照组,每组38例。观察组采用索拉非尼+斑螯酸钠维生素B6+TACE治疗,对照组采用索拉非尼+TACE治疗。记录两组患者的血清肝功能指标、血清VEGF和血清肿瘤标志物水平的变化情况,对比两组疗效及安全性。结果:治疗后,观察组患者血清总胆红素(serum Bilirubin,TBiL)、谷丙转氨酶(alanine aminotransferase,ALT)、VEGF、甲胎蛋白(alpha fetoprotein,AFP)、糖类抗原19-9(carbohydrate antigen,CA19-9)、高尔基蛋白73(golgi protein,GP73)较治疗前明显降低,且低于对照组(P<0.05),而血浆白蛋白(plasma albumin,ALB)较治疗前升高(P<0.05),且高于对照组(P<0.05)。观察组近期疗效有效率(92.11%)高于对照组(71.05%,P<0.05)。两组患者的各项不良反应发生率无统计学差异(P>0.05)。结论:联合斑螯酸钠维生素B6能够进一步提高索拉非尼+TACE对原发性肝癌的近期疗效。

Objective:To explore the therapeutic effects of sorafenib combined with disodium cantharidinate vitamin B6 on patients with primary liver cancer treated by transcatheter arterial chemoembolization(TACE),and the influence on their serum vascular endothelial growth factor(VEGF)and tumor markers.Methods:A total of 76 patients with primary liver cancer treated in our hospital from December 2018 to December 2019 were included and randomly divided into observation group and control group,with 38 cases in each group.The control group was treated with sorafenib and TACE,while the observation group was given additional disodium cantharidinate vitamin B6 on that basis.The serum liver function indexes,serum VEGF,serum tumor marker levels,efficacy and safety in two groups were recorded and compared.Results:After treatment,serum total bilirubin(serum Bilirubin,TBiL),alanine aminotransferase(ALT),VEGF,alpha fetoprotein(AFP),carbohydrate antigen 19-9(CA19-9),Golgi protein 73(Golgi protein,GP73)in observation group declined obviously,and was significantly lower than that in the control group(P<0.05).Plasma albumin(ALB)increased significantly(P<0.05)in observation group,and was higher than that in the control group(P<0.05).The short-term efficacy rate of the observation group was significantly higher than that of the control group(92.11%vs 71.05%,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Disodium cantharidinate vitamin B6 can further improve the short-term efficacy of sorafenib and TACE on primary liver cancer.